BPC-157 Compounding Pharmacy Quality Red Flags to Avoid

What FDA says about BPC-157 itself

BPC-157 is a synthetic peptide of 15 amino acids with a molecular weight of about 1419.5 g/mol, described as a fragment of a protein first isolated from human gastric juice. It is made as a free base or as an acetate salt, and FDA treats those as two different bulk substances [1].

No FDA-approved drug contains it, there is no US Pharmacopeia or National Formulary monograph for it, and FDA's July 2026 review found no approved product containing BPC-157 in any country it searched [1].

FDA's own reviewers, in a July 2026 briefing, wrote that the peptide is not well characterized chemically, that little is known about its safety and immunogenicity, that the evidence for the use FDA evaluated (ulcerative colitis) is insufficient, and that several approved drugs already treat that condition [1]. How BPC-157 is supposed to work in people is unknown; FDA said its molecular targets have not been identified and its mechanisms remain poorly understood [1].

Red flag 1: approval and 'legal to compound' claims

On FDA's list of nominated bulk substances for state-licensed pharmacies and physicians, updated May 14, 2026, BPC-157 appears in none of the three categories. Category 1 is the group FDA says it generally will not act against compounders for, if the conditions are met, so that policy does not cover BPC-157 [2]. It is also not on FDA's list for outsourcing facilities, updated March 21, 2025 [3]. FDA has not banned BPC-157 by name; it is an unapproved substance, and its compounding status is set by the bulk-substance rules and the draft policy described below [2].

A second version of this claim is that BPC-157 was cleared when it left FDA's category 2 list. It was in category 2, the significant-safety-risk group, from September 2023 until April 22, 2026. It came off because the groups that nominated it for FDA's pharmacy bulks list withdrew their nominations, not because of a safety finding. FDA's page still carries its stated concerns [4].

Those concerns, in FDA's words, are that compounded BPC-157 may pose a risk of immunogenicity for certain routes of administration and may have problems with peptide-related impurities and characterization of the active ingredient. FDA said it has identified no, or only limited, safety-related information for the proposed routes of administration and lacks sufficient information to know whether the drug would cause harm when given to humans [4].

Red flag 2: the 2026 vote and the HHS policy sold as approval

On July 23, 2026, FDA's Pharmacy Compounding Advisory Committee voted in favor of adding BPC-157 to the pharmacy bulks list, against FDA staff's recommendation [5][9]. Advisory committees make non-binding recommendations [5]. The vote did not put BPC-157 on the list; adding it requires formal rulemaking, meaning a proposed rule, public comment and a final rule [9].

On October 28, 2026, HHS filed a notice announcing a draft enforcement-discretion policy for six peptides, BPC-157 among them, with Federal Register publication scheduled for October 30, 2026 and public comments open for two weeks after publication. HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding with a listed peptide while FDA's list is developed through rulemaking, if the policy's conditions are met [6][9].

The notice itself says the policy does not establish any rights for any person and is not binding on HHS or the public, and HHS may revisit it, for example if a safety signal or product quality issue appears [6]. It is not an approval and does not put BPC-157 on any list [9].

Red flag 3: claims of a BPC-157 USP standard or documented quality testing

There is no US Pharmacopeia or National Formulary monograph for BPC-157 [1]. A label, certificate or sales page that calls BPC-157 USP-grade is invoking a standard that does not exist for this peptide.

Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are marketed [3].

Red flag 4: 'for research use only' stock sold as a human product

FDA noted websites selling BPC-157, alone or blended with TB-500, as capsules, injections, oral sprays and nasal sprays, some labeled 'for research purposes only and not for human or veterinary use'. Those products are not FDA-approved drugs [1]. A seller that uses research-only language while marketing to people is selling an unapproved product outside any approval pathway.

What the draft policy says a preparation would have to show

The October 2026 HHS notice lists specific conditions. Under the draft, the conditions for BPC-157 are: BPC-157 acetate only, in subcutaneous, intramuscular, oral or topical forms; a single active ingredient; bulk substance from an FDA-registered manufacturer with a valid certificate of analysis that meets a peptide testing standard; a label reading 'This is a compounded drug product. Not for resale.'; a patient-specific prescription; serious adverse events and quality problems reported to FDA MedWatch; only an FDA 510(k)-cleared syringe as a co-packaged device; and, for oral forms, documentation of adequate bioavailability [9].

The draft policy describes conditions for enforcement discretion; it does not create an approval or a universal quality standard. Claims that BPC-157 is FDA-approved or listed are inaccurate, and the policy can be changed or withdrawn [9][6].

Red flag 5: forms outside the draft policy, and routes with no human data

FDA found no human studies of BPC-157 given by mouth, by subcutaneous injection, by nasal spray or on the skin, and no human pharmacokinetic data for any of those routes [1]. The draft policy includes oral forms, with documentation of adequate bioavailability, but does not list nasal spray; rectal and intravenous forms are also not named [9].

After rectal enemas in two early studies, BPC-157 was mostly not detectable in blood, and FDA judged that it appears not to be absorbed systemically by that route [1]. A nasal spray sold with confident dosing instructions has no human data behind its route, and the draft policy does not cover it [1][9].

Red flag 6: confident dosing and safety talk

There is no FDA-approved dose because there is no approved product [1]. The doses in the few small human reports vary widely: a rectal enema of up to 2 mg/kg daily for 8 days in healthy volunteers, and 80 mg daily for two weeks in ulcerative colitis; 2 to 4 mg injected into the knee once or twice; 10 mg injected into the bladder wall once; and 10 mg then 20 mg intravenously on two days in 2 healthy adults [1]. None of those is a recommended dose.

On safety, FDA's search of its adverse-event database through December 4, 2025 found 3 reports, all for injectable BPC-157: injection-site redness and swelling lasting 9 days in a patient who also used compounded thymosin; shortness of breath leading to an emergency room visit; and widespread skin and gum darkening that recurred on re-exposure to a BPC-157 plus TB-500 research product. FDA said it cannot tell whether BPC-157 caused these [1]. In the small human studies FDA reviewed, no serious adverse events were reported, but the studies were short, small and gave limited safety information [1].

Animal work produced signals rather than reassurance. In 28-day intramuscular studies, BPC-157 shortened clotting time (aPTT) in rats and prolonged it in dogs, and raised liver enzyme (ALT), glucose and triglyceride levels; longer studies and cancer-risk studies were not available [1].

Red flag 7: claims about how well it works

A 2026 systematic review searched to June 1, 2026 for human studies of BPC-157 in orthopaedic and regenerative use. Three studies covering 30 patients met the criteria: a retrospective chart review of intra-articular injections for knee pain (16 patients contacted), a retrospective pilot of bladder-wall injections for interstitial cystitis (12 women), and a two-person intravenous safety pilot. All were judged poor methodological quality, and the certainty of evidence was rated very low. The reviewers concluded BPC-157 should not be used clinically outside ethically approved, regulated, high-quality trials [7].

One more: claims about drug testing

WADA names BPC-157 in S0, the non-approved substances class, and it is prohibited at all times, in and out of competition [8]. It was first named as an example under S0 in the 2022 List and remains named in the 2027 List, which is in force from January 1, 2027 [11][12]. A seller who tells a tested athlete otherwise is wrong about a published fact.

What this comes down to

BPC-157 is not FDA-approved and is not on either of FDA's compounding bulk-substance lists, for state-licensed pharmacies or for outsourcing facilities [1][2][3]. HHS has also announced a draft, non-binding policy describing conditions under which it does not intend to take enforcement action, and HHS can change or withdraw that policy [6][9]. A source that describes the peptide as approved, as listed, as USP-grade, or as backed by solid human safety data is misdescribing the public record [1][2][3][7].